About this episode
In this episode Colby reviews his experiences at the MAPS conference in Denver, we review a couple of topics we missed around LSD and MDMA, and introduce psilocybin! References: Gotvaldova K, et al. "Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids" . International Journal of Molecular Sciences . 2023 (22): 14068. Halpern J, Roth BL "Hallucinogens and dissociative agents naturally growing in the United States". Pharmacology & Therapeutics . 2004; 102 (2): 131–8. Huberman A. The science of MDMA and its therapeutic uses: benefits and risks. Huberman Labs (podcast). 12 Jun 2023 Pollan M. How to change your mind: the new science of psychedelics . Penguin Press. 2019 Sumner R, et al. Microdosed LSD: Dose day outcomes from a home-administered randomized controlled trial. 2023. Unpublished (information from poster presentation at MAPS conference) Woolley DW, Campbell NK (1962). "Serotonin-like and antiserotonin properties of psilocybin and psilocin". Science . 3518. 136 (3518): 777–8 Vizeli P, et al. Genetic influence of Cyp2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis. Scientific Reports . 2021(11); 10851.